Loading stock data…
$142.70-0.59 (-0.41%)
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. in the Healthcare sector is trading at $142.70 with a market capitalization of $15.5B. Wall Street consensus targets $206.22 (28 analysts), implying a +44.5% move over the next 12 months. The stock is currently 23% below its 52-week high of $186.12, remaining 3.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $959.00M↑ | $814.50M↑ | $805.50M↑ | $794.90M↑ | $687.50M |
| Gross Profit | $935.80M↑ | $800.70M↑ | $787.90M↑ | $780.90M↑ | $677.20M |
| Operating Income | $153.00M↓ | $186.00M↓ | $227.90M↓ | $239.30M↑ | $145.60M |
| Net Income | $144.40M↓ | $197.90M↑ | $153.70M↓ | $209.50M↑ | $107.50M |
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dy...